
BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Japan's Axcelead DDP joins Eli Lilly TuneLab to advance AI drug discovery

June 18, 2026 | News

Axcelead DDP will contribute proprietary drug discovery data to TuneLab



Japan-based startup Axcelead Drug Discovery Partners (DDP), Inc. has entered a collaboration with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly).

Lilly TuneLab is designed to accelerate early stage discovery by enabling participating biotech partners to access drug discovery models trained on decades of Lilly's proprietary research data.

Under this collaboration, Axcelead DDP will be able to enhance prediction of drug-like properties across small molecules and antibody therapeutics, including ADME, safety, and preclinical attributes, accelerating AI-driven drug discovery and development.

Lilly TuneLab uses federated learning to collaboratively improve predictive models without participating companies sharing raw proprietary data, fostering a collaborative discovery ecosystem.

As part of this collaboration, Axcelead DDP will contribute proprietary drug discovery data to TuneLab, helping to improve the models, and will be able to utilise Lilly TuneLab models when working with its biotech customers to help advance their programmes. Axcelead DDP is the first contract research organisation to participate in TuneLab in this way.